Pemphigus vulgaris is an autoimmune disorder that causes blisters in the skin and mucous membranes. The disease can be symptomatized by abnormal blistering of the skin and the oral cavity, atypical scarring of the skin, urticaria, recurrent cutaneous abscess formation, weight loss, and acantholysis. Certain medications that can cause pemphigus vulgaris are chelating agents such as penicillamine, pyrazolones, non-steroidal anti-inflammatory drugs, rifampin, beta-lactam antibiotics, and angiotensin converting enzyme inhibitors. People having myasthenia gravis and thymomas are more susceptible to the occurrence of pemphigus vulgaris. F Hoffmann-La Roche AG is in the process of developing mycophenolate mofetil as an immunosuppressant for the treatment of pemphigus vulgaris. Principia Biopharma, Inc. is in the process of developing PRN1008 as a agammaglobulinaemia tyrosine kinase inhibitor for the treatment of pemphigus vulgaris. Some of the companies having the pipeline of pemphigus vulgaris include Syntimmune, Inc., Principia Biopharma, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.